当前位置: X-MOL 学术Lung Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance
Lung Cancer ( IF 4.5 ) Pub Date : 2021-08-06 , DOI: 10.1016/j.lungcan.2021.07.020
Di Liu 1 , Xinyan Xu 1 , Junmiao Wen 1 , Chi Zhang 2 , Min Fan 1
Affiliation  

Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown a high response rate and long progression-free survival in primary treatment of ALK-positive non-small-cell lung cancer (NSCLC). De novo resistance or refractory subtype is rare event. Herein, we identify the first case with serial next-generation sequencing (NGS) results that harboured a rare echinoderm microtubule associated protein like 4 gene (EML4) -ALK (breaking site at exon 19) fusion in a lung adenocarcinoma (LUAD) patient who acquired alectinib resistance rapidly (less than 3 months), followed by multi-drug resistance and short survival time.



中文翻译:

在肺腺癌和艾乐替尼耐药中鉴定 EML4-ALK 外显子 19 融合变体

艾乐替尼是一种高度选择性的间变性淋巴瘤激酶 (ALK) 抑制剂,在 ALK 阳性非小细胞肺癌 (NSCLC) 的初级治疗中显示出高反应率和长无进展生存期。新发耐药或难治亚型是罕见的事件。在这里,我们确定了第一个具有系列下一代测序 (NGS) 结果的病例,该病例在肺腺癌 (LUAD) 患者中含有罕见的棘皮动物微管相关蛋白,如 4 基因 ( EML4 ) -ALK (外显子 19 断裂位点) 融合,该患者获得性艾乐替尼耐药迅速(不到3个月),其次是多药耐药,生存时间短。

更新日期:2021-08-12
down
wechat
bug